New hope for Hard-to-Treat myeloma: REGN5458 available for compassionate use
NCT ID NCT05164250
First seen Nov 11, 2025 · Last updated May 15, 2026 · Updated 32 times
Summary
This program provides access to REGN5458 for patients with multiple myeloma that has come back or stopped responding to other treatments. The goal is to control the cancer and improve outcomes. Participants receive the drug under compassionate use, meaning it is given outside of a clinical trial when no other options are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.